JP2017538734A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538734A5
JP2017538734A5 JP2017532819A JP2017532819A JP2017538734A5 JP 2017538734 A5 JP2017538734 A5 JP 2017538734A5 JP 2017532819 A JP2017532819 A JP 2017532819A JP 2017532819 A JP2017532819 A JP 2017532819A JP 2017538734 A5 JP2017538734 A5 JP 2017538734A5
Authority
JP
Japan
Prior art keywords
alkyl
substituents
substituted
hydrogen
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017532819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538734A (ja
JP6568588B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/080604 external-priority patent/WO2016097347A1/en
Publication of JP2017538734A publication Critical patent/JP2017538734A/ja
Publication of JP2017538734A5 publication Critical patent/JP2017538734A5/ja
Application granted granted Critical
Publication of JP6568588B2 publication Critical patent/JP6568588B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017532819A 2014-12-19 2015-12-18 PI3Kβ阻害剤としてのイミダゾピリダジン誘導体 Expired - Fee Related JP6568588B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199322.0 2014-12-19
EP14199322 2014-12-19
PCT/EP2015/080604 WO2016097347A1 (en) 2014-12-19 2015-12-18 IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS

Publications (3)

Publication Number Publication Date
JP2017538734A JP2017538734A (ja) 2017-12-28
JP2017538734A5 true JP2017538734A5 (cg-RX-API-DMAC7.html) 2018-11-08
JP6568588B2 JP6568588B2 (ja) 2019-08-28

Family

ID=52134002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017532819A Expired - Fee Related JP6568588B2 (ja) 2014-12-19 2015-12-18 PI3Kβ阻害剤としてのイミダゾピリダジン誘導体

Country Status (26)

Country Link
US (1) US10087187B2 (cg-RX-API-DMAC7.html)
EP (1) EP3233862B1 (cg-RX-API-DMAC7.html)
JP (1) JP6568588B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170095239A (cg-RX-API-DMAC7.html)
CN (1) CN107108634B (cg-RX-API-DMAC7.html)
AU (1) AU2015366190B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017012930A2 (cg-RX-API-DMAC7.html)
CA (1) CA2967551A1 (cg-RX-API-DMAC7.html)
CY (1) CY1122381T1 (cg-RX-API-DMAC7.html)
DK (1) DK3233862T3 (cg-RX-API-DMAC7.html)
EA (1) EA029789B1 (cg-RX-API-DMAC7.html)
ES (1) ES2761051T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191550T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045220T2 (cg-RX-API-DMAC7.html)
IL (1) IL252866B (cg-RX-API-DMAC7.html)
LT (1) LT3233862T (cg-RX-API-DMAC7.html)
MA (1) MA41174B1 (cg-RX-API-DMAC7.html)
MD (1) MD3233862T2 (cg-RX-API-DMAC7.html)
ME (1) ME03517B (cg-RX-API-DMAC7.html)
MX (1) MX2017008074A (cg-RX-API-DMAC7.html)
PL (1) PL3233862T3 (cg-RX-API-DMAC7.html)
PT (1) PT3233862T (cg-RX-API-DMAC7.html)
RS (1) RS59301B1 (cg-RX-API-DMAC7.html)
SI (1) SI3233862T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900509T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016097347A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526316B2 (en) 2015-10-09 2020-01-07 Janssen Pharmaceutica Nv Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors
ES2871140T3 (es) 2016-06-16 2021-10-28 Janssen Pharmaceutica Nv Derivados bicíclicos de piridina, pirazina y pirimidina como inhibidores de PI3K beta
BR112019020309A2 (pt) 2017-03-29 2020-04-28 Janssen Pharmaceutica Nv derivados de quinoxalina e piridopirazina como inibidores de pi3k-beta
WO2020160711A1 (en) 2019-02-07 2020-08-13 Beigene, Ltd. Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist
CN110128505A (zh) * 2019-05-21 2019-08-16 梯尔希(南京)药物研发有限公司 一种戈舍瑞林杂质的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
EP2046333A4 (en) 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
AR066477A1 (es) * 2007-05-09 2009-08-19 Novartis Ag Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
US20110046127A1 (en) * 2007-11-08 2011-02-24 Paolo Pevarello Imidazopyridazines for Use as Protein Kinase Inhibitors
KR20100128305A (ko) * 2008-02-28 2010-12-07 노파르티스 아게 C-met 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-b]피리다진 유도체
WO2010007099A1 (en) 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
EP3170813B1 (en) * 2010-10-06 2018-12-12 GlaxoSmithKline LLC Benzimidazole derivatives as pi3 kinase inhibitors
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
US8906910B2 (en) * 2011-12-20 2014-12-09 Glaxosmithkline Llc Imidazopyridine derivatives as PI3 kinase
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲pi3激酶調節劑的芳雜環化合物及其使用方法和用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents

Similar Documents

Publication Publication Date Title
JP2019518059A5 (cg-RX-API-DMAC7.html)
JP2017538734A5 (cg-RX-API-DMAC7.html)
JP2018535199A5 (cg-RX-API-DMAC7.html)
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
JP2015514808A5 (cg-RX-API-DMAC7.html)
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
JP2013527136A5 (cg-RX-API-DMAC7.html)
JP2018528946A5 (cg-RX-API-DMAC7.html)
JP2014518286A5 (cg-RX-API-DMAC7.html)
JP2017517565A5 (cg-RX-API-DMAC7.html)
JP2018516963A5 (cg-RX-API-DMAC7.html)
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
JP2014176384A5 (cg-RX-API-DMAC7.html)
JP2016516043A5 (cg-RX-API-DMAC7.html)
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
JP2016530259A5 (cg-RX-API-DMAC7.html)
JP2016515096A5 (cg-RX-API-DMAC7.html)
JP2016510326A5 (cg-RX-API-DMAC7.html)
JP2016528301A5 (cg-RX-API-DMAC7.html)
JP2013032389A5 (cg-RX-API-DMAC7.html)
MX391861B (es) Composiciones de canabinoide y usos
JP2010523522A5 (cg-RX-API-DMAC7.html)
JP2016518385A5 (cg-RX-API-DMAC7.html)
JP2016503052A5 (cg-RX-API-DMAC7.html)
JP2017514910A5 (cg-RX-API-DMAC7.html)